NCI-2023-10539

A Phase 1/2 study of combined treatment with dupilumab (anti-IL-4Ra) and cemiplimab (anti-PD-1) in patients with early-stage, resectable NSCLC

This study is exploring a new way to treat early-stage non small cell lung cancer that can be removed with surgery. They're testing two drugs together: Dupilumab, which fights inflammation and Cemiplimab, which helps the immune system fight cancer. The goal is to find out if this combination treatment is safe and effective.

non-small cell lung cancers: A type of lung cancer with non small cells that grow too much and can spread to other parts of the body

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06088771

Clinical Trial Site: Sinai

To see all available clinical trials click here.